Update on Bone Marrow Collection and Stem Cell Transplantation

Ming Li¹, Keguan Guo² and Susumu Ikehara**

¹Department of Stem Cell Disorders, Kansai Medical University, Hirakata City, Osaka, Japan
²Department of Cardiac Surgery, Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China

Abstract

Bone marrow transplantation (BMT) is a powerful strategy for the treatment of leukemia, aplastic anemia, congenital immunodeficiency and autoimmune diseases. In humans, bone marrow cells (BMCs) have usually been collected by multiple bone marrow aspirations from the iliac crest. We have established a new “perfusion” method for collecting BMCs with minimal contamination with the peripheral blood using the long bones of cynomolgus monkeys. This method has proven to be a safe and simple method for harvesting BMCs and reduces the risk of acute graft versus host disease in allogeneic BMT. Intra-bone marrow-BMT (IBM-BMT) provides distinct advantages because it recruits donor-derived hematopoietic stem cells and mesenchymal stem cells. IBM-BMT has been shown to currently be the best strategy for allogeneic BMT. Here we review the perfusion method (for harvesting BMCs) and IBM-BMT (for their transplantation) and show that this combination will become a powerful new clinical strategy for allogeneic BMT.

Keywords: Perfusion method; Intra-bone marrow-bone marrow transplantation; Bone marrow cells; Allogeneic bone marrow transplantation; Graft versus host disease

Abbreviations: AM: Aspiration Method; BMT: Bone Marrow Transplantation; BM: Bone Marrow; BMCs: Bone Marrow Cells; GvHD: Graft Versus-host Disease; HSCs: Hematopoietic Stem Cells; IBM-BMT: Intra-bone Marrow-BMT; IV-BMT: Intravenously Injected-BMT; MHC: Major Histocompatibility Complex; MSCs: Mesenchymal Stem Cells; PM: Perfusion Method

Introduction

Bone marrow transplantation (BMT) is a powerful strategy for the treatment of hematologic disorders, including leukemia and autoimmune diseases [1-3]. Furthermore, gene therapy and organ transplantation have been performed using bone marrow cells (BMCs) [4-8]. We have established a new perfusion method for collecting BMCs using the long bones of cynomolgus monkeys [9]. This method is simple, safe and is better for obtaining pure BMCs, resulting in a decreased incidence of acute graft versus-host disease (GvHD) in allogeneic BMT.

In animal experiments, intra-bone marrow-BMT (IBM-BMT) has been shown to efficiently recruit not only donor-derived hematopoietic stem cells (HSCs) but also mesenchymal stem cells (MSCs) [5,10,11]. HSCs can normally proliferate in major histocompatibility complex (MHC)-compatible MSCs even in allogeneic microenvironments. One report has suggested the potential of mesenchymal stoma cells as a novel cell therapy to prevent allograft rejection and interstitial fibrosis/tubular atrophy after kidney transplantation [12].

Aspiration Method (AM) and Perfusion Method (PM) for Harvesting BMCs

In humans, BMT is conventionally carried out by first collecting BMCs using multiple bone marrow (BM) aspirations from the iliac crest according to the method established by Thomas et al. [13]. The BM needles are inserted into the iliac bones more than 100 times. However, when using this AM, the BMCs are contaminated with peripheral blood with the result that there are more than 20% of T cells in the BMCs, which in turn leads to the induction of GvHD. When the thus-collected cells are intravenously injected (IV-BMT), most become trapped in the lung and only a few are able to migrate to the BM [14].

Nonhuman primates have similar stem and progenitor cell dynamics to humans and have been invaluable in developing and assessing new therapeutic transplant approaches for the treatment of human diseases [15-17]. The nonhuman primate studies closely model a clinical setting and should have broad applications for HSC gene therapy targeting human diseases of malignant, genetic and infectious nature [18]. Monkey mesenchymal stem cells (MSCs) have been shown to have similar features with human MSCs, thus providing important information for human therapies [19,20].

Using cynomolgus monkeys, we have established a new BMC harvesting method, which we call the PM (Figure 1A). This method minimizes the contamination of BMCs with T cells. Briefly, two needles are inserted into a long bone such as the humerus or femur. The end of the extension tube is connected to one needle and the other end is placed in a syringe containing 0.5mL heparin. The other needle is connected to a syringe containing 30 mL of saline, and the saline is then pushed gently from the syringe into the medullary cavity to flush out the BM. The saline containing the BM fluid is then collected [14]. There is significantly less contamination with T cells when using the PM (<10%) than with the conventional AM (>20%). Furthermore, the number and progenitor activities of the cells harvested using the PM are greater than when using the conventional AM [9]. The loss of some important BMCs during the process of T cell-depletion is inevitable when whole BMCs are contaminated with a high percentage of T cells, such as when the BMCs are collected using the AM. In this case, T cells from the peripheral blood contaminate the BMCs, leading to undesirable results despite the use of various treatments such as anti-T cell Abs and immunosuppressants. However, with the PM, there

*Corresponding author: Susumu Ikehara, MD, Ph.D, Professor of Department of Stem Cell Disorders, Kansai Medical University, 2-5-1 Shinmachi, Hirakata City, Osaka 573-1010, Japan, Tel: 81-72-804-2451; Fax: 81-72-804-2454, E-mail: ikehara@hirakata.kmu.ac.jp

Received December 17, 2013; Accepted January 02, 2014; Published January 04, 2014


Copyright: © 2014 Li M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
is substantially less contamination with mature T cells, as confirmed by the RBC: WBC and lymphocyte:granulocyte ratios, which are significantly lower using the PM than the AM. BMCs collected using the PM contain more immature cells, such as myeloblasts and promyelocytes, than those collected by the AM. Moreover, CFU-C assays show that a higher percentage of hematopoietic progenitor cells can be obtained using the PM than AM (Table 1), again due to the low level of contamination with the peripheral blood. Enriched progenitor activity in the BMCs collected using the PM is advantageous for the recipients, since short-term reconstitution by donor cells can be attributed to these progenitors.

Although the number of BMCs decreases in the long bones with age, there is red BM in the ilium, even in older human subjects. BMCs harvested from the ilium of aged donors by the perfusion method can be used for BMT across major histocompatibility complex (MHC) barriers and for organ transplantation (combined with BMT) if the donors are brain dead. BMCs collected using the PM were transplanted directly into the bone marrow cavities of the long bones of recipient cynomolgus monkeys that had been pretreated with irradiation. IBM-BMT was performed on both right and left humeri rather than tibiae in the case of these monkeys [21].

**IBM-BMT**

IBM-BMT can be used to treat hematopoietic disorders, metabolic disorders and autoimmune diseases [22-24]. IBM-BMT (Figure 1B) has been proven to be more effective than IV-BMT [25], since it can replace not only the HSCs and MSCs to be recruited, thereby preventing the risk of graft rejection, but also allows the use of a mild conditioning regimen. IBM-BMT thus seems to be the best strategy for allogeneic BMT, since 1) no GvHD develops even if whole BMCs are injected; 2) no graft failure occurs even if the radiation dose is reduced; 3) hematopoietic recovery is rapid and 4) the restoration of T cell functions is complete even in donor-recipient combinations across MHC barriers [26].

Recently, there have been reports indicating that MSCs secrete a variety of factors that promote tissue repair, stimulate proliferation and differentiation of endogenous tissue progenitors and decrease inflammatory and immune reactions [27-29]. MSCs have been shown to modulate immunological responses via T-cell suppression [27,29-31]. The therapeutic benefit of MSCs extends to T cell-mediated diseases such as GvHD [32], Crohn’s disease [33] and the prevention of organ transplantation rejection [34]. Moreover, MSCs have been observed to migrate to the site of injury in acute tissue injuries of kidney [35], liver [36], lung [37] and heart [38]. BM-MSCs have the ability to modify and influence almost all the cells of the innate and adaptive immune systems, to interfere with and affect cellular proliferation, differentiation, maturation and function to induce an anti-inflammatory phenotype and to modulate the immune response mediated by BM-MSC soluble factors, including IL-6, M-CSF, IL-10, TGFβ, HGF and PGE2 [29,39,40]. MSCs modulate DC function, indirectly regulate T and B cell activity, delay and prevent the development of GvHD [41] and suppress DC function during allogeneic islet transplantation [42].

BM-MSCs modulate different aspects of the rejection process, including the inhibition of DC differentiation [43], skewing of CD4+ T helper population phenotypes and modulation of CD8+ cytotoxic T lymphocyte and NK cell functions [20]. BM-MSCs strongly inhibited the maturation and functioning of monocyte-derived DCs by interfering selectively with the generation of immature cells via inhibitory mediator of MSC-derived PGE2 [44].

**Application of IBM-BMT in Animals**

We have succeeded in treating intractable autoimmune diseases in chimeric-resistant MRL/lpr mice using IBM-BMT [25]. In addition, IBM-BMT can effectively induce organ-specific tolerance, which leads to the success of organ transplantation, including skin [45], pancreas [46], leg [47] and heart [5]. Moreover, donor cell engraftments can be achieved even with reduced radiation doses and without using any immunosuppressants [5]. We previously showed that KK-Ay mice, a type 2 DM model reconstituted with KK-Ay bone marrow cells, showed glycosuria, hyperinsulinemia and hyperlipidemia. However, KK-Ay mice showed improved serum insulin and lipid levels 4 months after BMT from normal BALB/c mice [23]. A previous report suggested that the transplantation of BM-MSCs via IBM-BMT in conjunction with the induction of HO-1 could eradicate type 2 DM. The beneficial effect of HO-1 induction further suggests that the abnormality in endothelial progenitor cells is due to a MSC-stromal cell disorder exacerbated by oxidative stress and decreases in adiponectin [48]. IBM-BMT+ thymus
transplantation (TT) has been shown to induce adiponectin secretion, follow by enhanced pLKB1-AKT-AMPK signaling pathway, upregulation of HO-1 expression, while decreasing iNOS levels in the kidney of db/db mice [49,50].

IBM-BMT has become an established method and has already been applied to humans [51,52]. IBM-BMT has been reported to be superior to IV-BMT in severe combined immunodeficient mice reconstituted with human cells [53-55]. IBM-BMT can efficiently transfer donor whole BMCs into recipients and this method can therefore be used to quickly replace not only donor-derived-HSCs but also MSCs.

Conclusion

As discussed, the PM is applicable to the long bones in monkeys but is also applicable to the iliac bones. That no accidents occurred when using the PM to obtain BMCs from either the long bones or the iliac bones in monkeys indicates that both the PM and IBM-BMT are safe and can be applied to humans [56]. The PM can efficiently be used to collect whole BMCs, including HSCs and MSCs, without them being contaminated with T cells, and no GVHD therefore develops. We believe that the combination of the PM and IBM-BMT will become a powerful new strategy for allogenic BMT and regeneration therapy.

Acknowledgments

We would like to thank Mr. Hilary Eastwick-Field and Ms. Keiko Ando for their help in the preparation of the manuscript.

Conflict of Interests

None of the authors have conflicts of interest to declare.

References


Table 1: Comparing AM and PM for Harvesting BMCs.

<table>
<thead>
<tr>
<th>AM</th>
<th>PM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insert times</td>
<td>more less</td>
</tr>
<tr>
<td>T cells contamination</td>
<td>high low</td>
</tr>
<tr>
<td>Number of hematopoietic progenitors</td>
<td>low high</td>
</tr>
<tr>
<td>Ratio of RBC/WBC</td>
<td>high low</td>
</tr>
<tr>
<td>Ratio of lymphocyte:granulocyte</td>
<td>high low</td>
</tr>
</tbody>
</table>


